Which has better earnings & valuation, SEPN or IMVT?

Septerna has higher revenue and earnings than Immunovant. Septerna is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 38.98 -$48.88M -$0.54 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is SEPN or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -24.51% -9.57% -6.28% Immunovant N/A -69.59% -62.49%

Which has stronger valuation & earnings, ALKS or SEPN?

Alkermes has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.67B 4.09 $241.66M $0.38 106.87 Septerna $45.95M 38.98 -$48.88M -$0.54 N/A

Is ALKS or SEPN more profitable?

Alkermes has a net margin of 3.96% compared to Septerna's net margin of -24.51%. Alkermes' return on equity of 4.15% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Septerna -24.51% -9.57% -6.28%

Which has better earnings and valuation, CGON or SEPN?

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,400.25 -$160.99M -$2.69 N/A Septerna $45.95M 38.98 -$48.88M -$0.54 N/A

Is CGON or SEPN more profitable?

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Septerna -24.51% -9.57% -6.28%

Septerna (SEPN) Competitors

$38.37 +1.47 (+3.98%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$38.89 +0.52 (+1.35%)

As of 10/9/2026 07:54 PM Eastern

Compare

SEPN vs. IMVT, ALKS, RYTM, IOVA, and CGON

Should you buy Septerna stock or one of its competitors? Septerna's main competitors and comparable companies include Immunovant (IMVT), Alkermes (ALKS), Rhythm Pharmaceuticals (RYTM), Iovance Biotherapeutics (IOVA), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Septerna compare to Immunovant?

Septerna (NASDAQ:SEPN) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Immunovant had 13 more articles in the media than Septerna. MarketBeat recorded 14 mentions for Immunovant and 1 mentions for Septerna. Septerna's average media sentiment score of 1.46 beat Immunovant's score of 0.45 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Positive
Immunovant	Neutral

Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Immunovant	N/A	-69.59%	-62.49%

Septerna has higher revenue and earnings than Immunovant. Septerna is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

47.1% of Immunovant shares are held by institutional investors. 5.8% of Septerna shares are held by company insiders. Comparatively, 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Septerna currently has a consensus target price of $52.44, suggesting a potential upside of 36.68%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 44.40%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Septerna beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Septerna compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Alkermes presently has a consensus price target of $54.47, indicating a potential upside of 34.13%. Septerna has a consensus price target of $52.44, indicating a potential upside of 36.68%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Alkermes has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.09	$241.66M	$0.38	106.87
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alkermes had 6 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Alkermes and 1 mentions for Septerna. Septerna's average media sentiment score of 1.46 beat Alkermes' score of 0.46 indicating that Septerna is being referred to more favorably in the news media.

Company	Overall Sentiment
Alkermes	Neutral
Septerna	Positive

Alkermes has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market.

Alkermes has a net margin of 3.96% compared to Septerna's net margin of -24.51%. Alkermes' return on equity of 4.15% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Septerna	-24.51%	-9.57%	-6.28%

Summary

Alkermes beats Septerna on 11 of the 17 factors compared between the two stocks.

How does Septerna compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Septerna has a net margin of -24.51% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Septerna's return on equity of -9.57% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Septerna	-24.51%	-9.57%	-6.28%

Rhythm Pharmaceuticals has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus target price of $140.89, suggesting a potential upside of 55.20%. Septerna has a consensus target price of $52.44, suggesting a potential upside of 36.68%. Given Rhythm Pharmaceuticals' higher possible upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Septerna has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.78	-$196.54M	-$3.11	N/A
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Septerna. MarketBeat recorded 2 mentions for Rhythm Pharmaceuticals and 1 mentions for Septerna. Septerna's average media sentiment score of 1.46 beat Rhythm Pharmaceuticals' score of 0.53 indicating that Septerna is being referred to more favorably in the news media.

Company	Overall Sentiment
Rhythm Pharmaceuticals	Positive
Septerna	Positive

Summary

Septerna beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Septerna compare to Iovance Biotherapeutics?

Septerna (NASDAQ:SEPN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Septerna has higher earnings, but lower revenue than Iovance Biotherapeutics. Septerna is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A
Iovance Biotherapeutics	$263.50M	25.13	-$390.98M	-$0.73	N/A

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Septerna. MarketBeat recorded 9 mentions for Iovance Biotherapeutics and 1 mentions for Septerna. Septerna's average media sentiment score of 1.46 beat Iovance Biotherapeutics' score of 0.77 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Positive
Iovance Biotherapeutics	Positive

Septerna has a net margin of -24.51% compared to Iovance Biotherapeutics' net margin of -89.11%. Septerna's return on equity of -9.57% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-24.51%	-9.57%	-6.28%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Septerna currently has a consensus price target of $52.44, suggesting a potential upside of 36.68%. Iovance Biotherapeutics has a consensus price target of $12.90, suggesting a potential downside of 11.76%. Given Septerna's stronger consensus rating and higher possible upside, equities analysts clearly believe Septerna is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Iovance Biotherapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Septerna has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Septerna beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Septerna compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Septerna (NASDAQ:SEPN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CG Oncology currently has a consensus target price of $87.50, indicating a potential upside of 37.10%. Septerna has a consensus target price of $52.44, indicating a potential upside of 36.68%. Given CG Oncology's higher possible upside, equities research analysts clearly believe CG Oncology is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

CG Oncology has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

In the previous week, CG Oncology had 1 more articles in the media than Septerna. MarketBeat recorded 2 mentions for CG Oncology and 1 mentions for Septerna. Septerna's average media sentiment score of 1.46 beat CG Oncology's score of 0.67 indicating that Septerna is being referred to more favorably in the news media.

Company	Overall Sentiment
CG Oncology	Positive
Septerna	Positive

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,400.25	-$160.99M	-$2.69	N/A
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A

Septerna has a net margin of -24.51% compared to CG Oncology's net margin of -3,602.68%. Septerna's return on equity of -9.57% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Septerna	-24.51%	-9.57%	-6.28%

Summary

Septerna beats CG Oncology on 11 of the 16 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.72B	$3.86B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-71.06	13.42	274.15	26.16
Price / Sales	38.98	1,234.39	635.98	107.42
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	4.50	17.17	11.21	6.34
Net Income	-$48.88M	-$22.69M	$3.50B	$381.90M
7 Day Performance	1.75%	-1.33%	-0.90%	-1.41%
1 Month Performance	1.64%	-8.44%	-4.44%	-3.48%
1 Year Performance	66.32%	14.02%	6.96%	1.16%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	2.756 of 5 stars	$38.37 +4.0%	$52.44 +36.7%	+65.8%	$1.72B	$45.95M	N/A	130	Positive News
IMVT Immunovant	2.5859 of 5 stars	$33.46 -0.1%	$44.00 +31.5%	+74.3%	$6.91B	N/A	N/A	315	News Coverage Insider Trade
ALKS Alkermes	3.2846 of 5 stars	$40.80 +1.6%	$54.47 +33.5%	+29.4%	$6.84B	$1.48B	107.37	2,050
RYTM Rhythm Pharmaceuticals	2.8301 of 5 stars	$95.71 -2.9%	$140.67 +47.0%	-9.4%	$6.56B	$189.76M	N/A	414	Analyst Forecast
IOVA Iovance Biotherapeutics	2.4184 of 5 stars	$14.45 +31.5%	$11.78 -18.5%	+567.6%	$6.55B	$263.50M	N/A	975	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. IMVT, ALKS, RYTM, IOVA, and CGON

How does Septerna compare to Immunovant?

Summary

How does Septerna compare to Alkermes?

Summary

How does Septerna compare to Rhythm Pharmaceuticals?

Summary

How does Septerna compare to Iovance Biotherapeutics?

Summary

How does Septerna compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. IMVT, ALKS, RYTM, IOVA, and CGON

How does Septerna compare to Immunovant?

Does the media refer more to SEPN or IMVT?

Which has more risk & volatility, SEPN or IMVT?

Is SEPN or IMVT more profitable?

Which has better earnings & valuation, SEPN or IMVT?

Do institutionals & insiders hold more shares of SEPN or IMVT?

Do analysts prefer SEPN or IMVT?

Summary

How does Septerna compare to Alkermes?

Do analysts prefer ALKS or SEPN?

Which has stronger valuation & earnings, ALKS or SEPN?

Do institutionals and insiders have more ownership in ALKS or SEPN?

Does the media favor ALKS or SEPN?

Which has more risk and volatility, ALKS or SEPN?

Is ALKS or SEPN more profitable?

Summary

How does Septerna compare to Rhythm Pharmaceuticals?

Is RYTM or SEPN more profitable?

Which has more risk and volatility, RYTM or SEPN?

Do analysts rate RYTM or SEPN?

Which has stronger valuation & earnings, RYTM or SEPN?

Does the media prefer RYTM or SEPN?

Summary

How does Septerna compare to Iovance Biotherapeutics?

Do insiders & institutionals have more ownership in SEPN or IOVA?

Which has preferable valuation & earnings, SEPN or IOVA?

Does the media refer more to SEPN or IOVA?

Is SEPN or IOVA more profitable?

Do analysts recommend SEPN or IOVA?

Which has more risk and volatility, SEPN or IOVA?

Summary

How does Septerna compare to CG Oncology?

Do insiders & institutionals believe in CGON or SEPN?

Do analysts prefer CGON or SEPN?

Which has more volatility & risk, CGON or SEPN?

Does the media prefer CGON or SEPN?

Which has better earnings and valuation, CGON or SEPN?

Is CGON or SEPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools